AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03489941
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Trial: NCT03631654
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01653327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02464865
Drug: Thiamine 1
RxNorm normalized name: thiamine 10 MG
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks
Trial: NCT02464865
Drug: Thiamine 2
RxNorm normalized name: thiamine 2 MG
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks
Trial: NCT00003215
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003215
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003215
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003215
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003215
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003215
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750256
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
Trial: NCT00047788
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00047788
Drug: VEGF-receptor tyrosine kinase (KDR)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01738191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03863691
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
Trial: NCT04263038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug without active agent
Trial: NCT03597139
Drug: Restasis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT04209439
Drug: Dexketoprofen-trometamol
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Dexketoprofen-trometamol intravenous
Trial: NCT01994473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose placebo
Trial: NCT02737670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet morning and evening for 40 days
Trial: NCT01770067
Drug: CITA-RNPT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02107950
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
Trial: NCT00467402
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03338569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo designed to mimic intervention
Trial: NCT01120132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered during 28 days
Trial: NCT03341117
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 300 mg per capsule
Trial: NCT03118479
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgel 7.5 g to be applied transdermally daily for 3 months.
Trial: NCT03118479
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet to be taken daily for 3 months
Trial: NCT03461302
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasone butyrate 0.05% ointment
Trial: NCT02169388
Drug: placebo（for probiotic）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microbiota modulation using placebo
Trial: NCT05049473
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Trial: NCT05049473
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
Trial: NCT05049473
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
Trial: NCT05049473
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Trial: NCT05049473
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
Trial: NCT04338191
Drug: mFOLFOXIRI adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
Trial: NCT04338191
Drug: mFOLFOX6 adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
Trial: NCT04679948
Drug: Percoffedrinol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04679948
Drug: Coumadin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04679948
Drug: Antra MUPS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant tablet
Trial: NCT00028522
Drug: R(+)XK469
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00650286
Drug: Provigil® Tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, single dose fed
Trial: NCT03710369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill was compounded by McDonalds Pharmacy.
Trial: NCT02068859
Drug: Diclofenac Cream 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Trial: NCT02068859
Drug: Diclofenac Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Trial: NCT05535322
Drug: SGLT2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
Trial: NCT05535322
Drug: Miscellany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
Trial: NCT00233207
Drug: IC14
RxNorm normalized name: CATH,INTERMIT 14FR RELIAMED #PIC1416
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00671125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Trial: NCT01048086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in the same manner as retinoic acid in capsules that look identical.
Trial: NCT01004978
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo TACE
Trial: NCT01004978
Drug: Doxorubicin-Eluting Beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo TACE
Trial: NCT02215499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03749109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00417144
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01356329
Drug: Enoxaparin, Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.
Trial: NCT00661453
Drug: Valproic Acid and Levocarnitine
RxNorm normalized name: levocarnitine / picolinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
Trial: NCT02000882
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04114656
Drug: GSK3858279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
Trial: NCT00642603
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
Trial: NCT00259428
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03334422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04104997
Drug: 5% GLH8NDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% GLH8NDE as eye drops
Trial: NCT04104997
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as eye drops
Trial: NCT01716611
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00994214
Drug: BIM 23A760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Trial: NCT00153816
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; two tablets per day
Trial: NCT04571385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to AP30663.
Trial: NCT03079973
Drug: P-3073 (calcipotriene 0.005%)
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
Trial: NCT03079973
Drug: Vehicle of P-3073
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 24 weeks.
Trial: NCT02119806
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
Trial: NCT02087943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally twice a day (BID)
Trial: NCT02493530
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established.
Trial: NCT01129375
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Trial: NCT02074800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single-dose of matching placebo intravenously in Part 1.
Trial: NCT00983541
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
Trial: NCT00590538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is given to match the active comparator for four days.
Trial: NCT02109406
Drug: AZD2115 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD 2115, Dose 1 administered as two inhalations BID
Trial: NCT02109406
Drug: AZD 2115, Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD 2115, Dose 2 administered as two inhalations BID
Trial: NCT02109406
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI administered as two inhalations BID
Trial: NCT02944435
Drug: CB-839 Capsules
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 200 mg CB-839 Capsules (Reference Formulation)
Trial: NCT02944435
Drug: CB-839 Tablets
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 200 mg CB-839 Tablets (Test Formulation)
Trial: NCT01118572
Drug: etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01118572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01303614
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
Trial: NCT00703118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
Trial: NCT04046822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Trial: NCT01608516
Drug: 68Ga-NODAGA-RGD PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
Trial: NCT03167255
Drug: NS-065/NCNP-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received during weekly intravenous infusions
Trial: NCT01162889
Drug: ATR-107 (PF-05230900) SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous infusion, 60 minute duration
Trial: NCT02452255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months
Trial: NCT00814541
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01162889
Drug: ATR-107 (PF-05230900) SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single subcutaneous injection
Trial: NCT01162889
Drug: ATR-107 (PF-05230900) IV Infusion
RxNorm normalized name: SET,INFUSION MINIMED #MMT-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion, 60 minute duration
Trial: NCT00520052
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
Trial: NCT03013985
Drug: Glulisine Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
Trial: NCT03738761
Drug: Amlessa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
Trial: NCT03738761
Drug: Co-Amlessa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
Trial: NCT00099177
Drug: ibandronate [Bondronat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg iv on days 1-3, and 50mg po from day 22 to week 24
Trial: NCT00099177
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg iv on day 1, and every 3-4 weeks
Trial: NCT03681184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by SC injection
Trial: NCT03174288
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of spironolactone
Trial: NCT00103298
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02156063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00196430
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04517045
Drug: Dachengqi decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
Trial: NCT04517045
Drug: probiotic L9
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L92 2 tablets/time, tid, oral or nasal feeding
Trial: NCT01380691
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01380691
Drug: Placebo-matching LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01380691
Drug: Placebo-matching alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01380691
Drug: Alcoholic beverage
RxNorm normalized name: Alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00006110
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenous infusion every 3 weeks for four cycles
Trial: NCT00006110
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
Trial: NCT01516645
Drug: KHK2898
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT02897063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT03609190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of NaCl over 40 min